Abstract
In the third millennium preventive medicine is becoming a corner stone in our concept of health. Colorectal cancer (CRC) fits the criteria of a disease suitable for prevention interventions. It is a prevalent disease that is associated with considerable mortality and morbidity rates, with more than 1,000,000 new cases and 500,000 deaths annually. CRC has a natural history of transition from precursor to malignant lesion that spans, on average, 10-15 years, providing a window of opportunity for effective interventions and prevention. Indeed, CRC is preventable in up to 90% of the cases. Simple life style modifications (balanced diet avoidance of smoking and alcohol, and moderate physical activity) can prevent up to 50% of the cases of colorectal cancer. compliance with current screening methods is a major barrier to the achievement of optimal results, a large part of the average risk population has not been screened by any method. Several newly developed screening modalities, such as the virtual colonoscopy and stool genetic testing may improve compliance. In addition, chemoprevention, a new science that has emerged during the last decade, presents an alternative approach to reducing mortality from colorectal cancer as well as other cancers. Chemoprevention involves the long-term use of a variety of oral agents that can delay, prevent or even reverse the development of adenomas in the large bowel. In light of the recent evidence of the efficacy of chemoprevention in persons at high risk for CRC cancer, it seems only appropriate to consider similar strategies for the general population.
Keywords: Colorectal cancer, prevention, chemoprevention, cyclooxygenase-2, screening, dietary changes, life style
Current Pharmaceutical Design
Title: Current and Future Clinical Strategies in Colon Cancer Prevention and the Emerging Role of Chemoprevention
Volume: 13 Issue: 22
Author(s): Ben Boursi and Nadir Arber
Affiliation:
Keywords: Colorectal cancer, prevention, chemoprevention, cyclooxygenase-2, screening, dietary changes, life style
Abstract: In the third millennium preventive medicine is becoming a corner stone in our concept of health. Colorectal cancer (CRC) fits the criteria of a disease suitable for prevention interventions. It is a prevalent disease that is associated with considerable mortality and morbidity rates, with more than 1,000,000 new cases and 500,000 deaths annually. CRC has a natural history of transition from precursor to malignant lesion that spans, on average, 10-15 years, providing a window of opportunity for effective interventions and prevention. Indeed, CRC is preventable in up to 90% of the cases. Simple life style modifications (balanced diet avoidance of smoking and alcohol, and moderate physical activity) can prevent up to 50% of the cases of colorectal cancer. compliance with current screening methods is a major barrier to the achievement of optimal results, a large part of the average risk population has not been screened by any method. Several newly developed screening modalities, such as the virtual colonoscopy and stool genetic testing may improve compliance. In addition, chemoprevention, a new science that has emerged during the last decade, presents an alternative approach to reducing mortality from colorectal cancer as well as other cancers. Chemoprevention involves the long-term use of a variety of oral agents that can delay, prevent or even reverse the development of adenomas in the large bowel. In light of the recent evidence of the efficacy of chemoprevention in persons at high risk for CRC cancer, it seems only appropriate to consider similar strategies for the general population.
Export Options
About this article
Cite this article as:
Ben Boursi and Nadir Arber , Current and Future Clinical Strategies in Colon Cancer Prevention and the Emerging Role of Chemoprevention, Current Pharmaceutical Design 2007; 13 (22) . https://dx.doi.org/10.2174/138161207781368783
DOI https://dx.doi.org/10.2174/138161207781368783 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Current Cancer Drug Targets Therapeutic Benefit and Biological Importance of Ginkgetin in the Medicine: Medicinal Importance, Pharmacological Activities and Analytical Aspects
Current Bioactive Compounds Kefir: A Synbiotic with Approved Anticarcinogenic Properties
Current Bioactive Compounds Therapeutic Application of Natural Medicine Monomers in Cancer Treatment
Current Medicinal Chemistry Nuclear Hormone Receptors and Female Reproduction
Current Molecular Medicine Diagnosis and Management of Lynch Syndrome
Recent Patents on Regenerative Medicine Free Radicals and Antioxidants: How to Reestablish Redox Homeostasis in Chronic Diseases?
Current Medicinal Chemistry Eliminating Ovarian Cancer Stem Cells: A Potential Therapeutic Target for Ovarian Cancer Chemoresistance
Current Protein & Peptide Science Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Relevance of Micrometastases and Targeting the Bone Marrow Niche with Zoledronic Acid in Breast Cancer
Current Cancer Therapy Reviews Targeting Platinum Resistant Disease in Ovarian Cancer
Current Medicinal Chemistry Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer
Current Clinical Pharmacology Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity
Current Medicinal Chemistry NF-κB Signaling and Carcinogenesis
Current Pharmaceutical Design Nutritional Targeting of Cyclooxygenase-2 for Colon Cancer Prevention
Inflammation & Allergy - Drug Targets (Discontinued) Mucosal Healing in Crohn’s Disease: Relevance for Clinical Outcomes
Current Drug Targets Comparative Proteomics and Bioinformatics Analysis of Tissue from Non-Small Cell Lung Cancer Patients
Current Proteomics DNA Microarray-Based Gene Expression Profiling in Cancer: Aiding Cancer Diagnosis, Assessing Prognosis and Predicting Response to Therapy
Current Pharmacogenomics Insulin Analogs Revisited
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents